Aptamer Technology: Adjunct Therapy for Malaria
AbstractMalaria is a life-threatening parasitic infection occurring in the endemic areas, primarily in children under the age of five, pregnant women, and patients with human immunodeficiency virus and acquired immunodeficiency syndrome (HIV)/(AIDS) as well as non-immune individuals. The cytoadherence of infected erythrocytes (IEs) to the host endothelial surface receptor is a known factor that contributes to the increased prevalence of severe malaria cases due to the accumulation of IEs, mainly in the brain and other vital organs. Therefore, further study is needed to discover a new potential anti-adhesive drug to treat severe malaria thus reducing its mortality rate. In this review, we discuss how the aptamer technology could be applied in the development of a new adjunct therapy for current malaria treatment. View Full-Text
Share & Cite This Article
Nik Kamarudin, N.A.A.; Mohammed, N.A.; Mustaffa, K.M.F. Aptamer Technology: Adjunct Therapy for Malaria. Biomedicines 2017, 5, 1.
Nik Kamarudin NAA, Mohammed NA, Mustaffa KMF. Aptamer Technology: Adjunct Therapy for Malaria. Biomedicines. 2017; 5(1):1.Chicago/Turabian Style
Nik Kamarudin, Nik A.A.; Mohammed, Nurul A.; Mustaffa, Khairul M.F. 2017. "Aptamer Technology: Adjunct Therapy for Malaria." Biomedicines 5, no. 1: 1.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.